Filing Flows › Monte Rosa Therapeutics (GLUE) › Recalls, complaints & regulation

Monte Rosa Therapeutics (GLUE): clinical trials

Monte Rosa Therapeutics (GLUE) beyond its filings: 3 active clinical trials.

Monte Rosa Therapeutics' latest quarter

Monte Rosa Therapeutics, Q3 2026: revenue $54.4M (+326% year over year), operating margin -3.6%, net earnings $3.1M, operating cash flow −$41.0M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Monte Rosa Therapeutics have?

3 active studies on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.